RIZ1基因在骨髓增生异常综合征中的表达及其意义  

Expression of RIZ1 gene in myelodysplastic syndromes and its significance

作　　者：叶芳[1] 王丽娜[2] 贾宁[2] 李宁宁[1] 王欢[1] Ye Fang;Wang Lina;Jia Ning;Li Ningning;Wang Huan(Department of Hematology,Chuiyangliu Hospital Affiliated to Tsinghua University,Beijing 100022,China;Department of Hematology,the Second Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]清华大学附属垂杨柳医院血液科,北京100022 [2]山西医科大学第二医院血液科,太原030001

出　　处：《肿瘤研究与临床》2019年第7期442-445,共4页Cancer Research and Clinic

基　　金：山西省科技攻关项目(20150313012-5);山西省留学基金([2009]9号106);山西省国际合作项目(2012081044-1);北京市朝阳区科学技术委员会项目(CYSF151510、CYSF1812).

摘　　要：目的探讨不同类型及不同危险度分级骨髓增生异常综合征(MDS)患者RIZ1mRNA的表达及其与临床特征的相关性。方法收集2014年1月至2017年12月清华大学附属垂杨柳医院及山西医科大学第二医院收治的46例初发MDS患者和10名健康对照者(均为造血干细胞移植术供者),采用实时荧光定量聚合酶链反应(RT-PCR)检测MDS患者及健康对照者骨髓细胞中RIZ1mRNA表达水平。结果与健康对照者相比,MDS患者的RIZ1mRNA相对表达量下降[中位数(P25,P75):0.557(0.333,0.815)比1.003(0.895,1.812)],差异有统计学意义(Z=-2.991,P=0.0003)。依据世界卫生组织(WHO)分型,难治性贫血/环形铁粒幼细胞性难治性贫血/难治性血细胞减少伴多系发育异常(RA/RAS/RCMD)、难治性贫血伴有原始细胞过多Ⅰ(RAEB-Ⅰ)、难治性贫血伴有原始细胞过多Ⅱ(RAEB-Ⅱ)、MDS转变成急性髓系白血病(MDS/AML)组和健康对照组的RIZ1mRNA相对表达量比较,差异有统计学意义(χ2=19.500,P<0.01);进一步两两比较结果显示,RAEB-Ⅰ、RAEB-Ⅱ、MDS/AML组的RIZ1mRNA相对表达量均低于健康对照组,差异均有统计学意义(均P<0.05)。依据国际预后评分系统(IPSS)分类,低危、中危-1、中危-2及高危组MDS患者和健康对照组的RIZ1mRNA相对表达量比较,差异有统计学意义(χ2=19.214,P=0.001);进一步两两比较结果显示,中危-1、中危-2及高危组的RIZ1mRNA相对表达量均低于健康对照组,差异均有统计学意义(均P<0.05),并且随疾病危险度分级升高,RIZ1mRNA表达呈下降趋势。RIZ1mRNA表达水平与患者年龄、性别、外周血白细胞计数、血红蛋白、血小板计数及染色体核型均无相关性(均P>0.05)。结论MDS患者RIZ1mRNA表达水平下降,且在不同类型及不同危险度分级中表达存在差异,该基因可能参与MDS发病机制,并与疾病进展有关。Objective To explore RIZ1 mRNA expression level in different subtypes and risk classification groups of the patients with myelodysplastic syndromes (MDS) and to analyze the correlation between the clinical features and RIZ1 mRNA expression. Methods A total of 46 newly diagnosed as MDS patients and 10 healthy controls who were the donors of hematopoietic stem cell transplantation from Chuiyangliu Hospital Affiliated to Tsinghua University and the Second Hospital of Shanxi Medical University between January 2014 and December 2017 were collected. The real time fluorescence quantitative polymerase chain reaction (RT-PCR) was used to detect the expression level of RIZ1 mRNA in bone marrow cells from MDS patients and the healthy controls. Results Compared with the healthy control group, the relative expression level of RIZ1 mRNA in MDS patients was decreased [the median (P25, P75): 1.003 (0.895, 1.812) vs. 0.557 (0.333, 0.815)], and the difference was statistically significant (Z=-2.991, P=0.000 3). According to the World Health Organization (WHO) classification criteria, compared with the healthy control group, the relative expression of RIZ1 mRNA in refractory anemia/refractory anemia with ring sideroblasts/refractory cytopenia with multiple dysplasia (RA/RAS/RCMD), refractory anemia with excess blasts Ⅰ(RAEB-Ⅰ), RAEB-Ⅱ and MDS transformed into acute myeloid leukemia (MDS/AML) groups had statistically significant differences (χ 2=19.500, P < 0.01). Further pairwise comparison showed that the relative expression level of RIZ1 mRNA in RAEB-Ⅰ, RAEB-Ⅱ and MDS/AML groups was lower than that in the healthy control group, and the differences were statistically significant (all P < 0.05). According to the international prognostic scoring system (IPSS), compared with the healthy control group, the expression of RIZ1 mRNA in low-risk, inter-risk-1, inter-risk-2 and high-risk group had statistical differences (χ 2=19.214, P=0.001). Further pairwise comparison showed that the relative expression of RIZ1 mRNA in inter

关 键 词：骨髓增生异常综合征 RIZ1基因 实时荧光定量聚合酶链反应 发病机制 

分 类 号：R551.3[医药卫生—血液循环系统疾病]